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A B S T R A C T
Objectives: Pulmonary embolism (PE) is associated with a substantial economic
burden. However evidence from patients in Europe is scarce. The aim of this study was to report the impacts of PE on healthcare resource utilization (HCRU) and
return to work using the PREFER in VTE registry.
Methods: The PREFER in VTE registry was a prospective, observational, multicenter study in seven European countries, aiming to provide data concerning treatment
patterns, HCRU, mortality, quality of life and work-loss. Patients with a ﬁrst-time or recurrent PE were included and followed up at 1, 3, 6 and 12months. Treatment
patterns, re-hospitalization rates, length of hospital stays (LOS), and ambulatory/oﬃce visits, as well as proportion of patients returning to work, were assessed.
Subgroups by country and with/without active cancer were examined separately. Zero-inﬂated negative binomial and Cox regression were applied to investigate the
relationship between baseline characteristics and LOS and return to work, respectively.
Results: Amongst 1399 patients with PE, 53.2% were male and the average age was 62.3 ± 17.1 years old. Overall, patients were treated with combinations of
heparin, vitamin K antagonists (VKA) and the non-VKA oral anticoagulants (NOACs) (50.0% treated with the combination of heparin with VKA). Patients with active
cancer were primarily treated with heparin (84.9%). NOACs were used more frequently in DACH (Germany, Austria and Switzerland) and France (55.2% and 32.6%)
compared to Italy and Spain (4.5% and 6.1%). The VTE-related re-hospitalization rate within 12months and the average LOS varied substantially between countries,
from 26.2% in UK to 12.3% in France, and from 12.9 days in Italy to 3.9 days in France. PE patients were often co-managed by general practitioners in France and
DACH (>84%), and less frequently in other countries (< 47%). The regression results conﬁrmed the country variation of HCRU. Of the employed patients
(n=385), 60% returned to work at 1month but 27.8% had not after one year. PE patients with DVT were more likely to return to work. Active cancer was a
signiﬁcant predictor for not returning to work, as well as smoking history.
Conclusions: Medical treatment of PE diﬀered between patients with active cancer and patients without active cancer. VTE-related resource utilization diﬀered
markedly between countries. While the reported ’not return to work’ was high for patients with PE, this may at least in part reﬂect the presence of co-morbidities such
as cancer.
1. Introduction
Pulmonary embolism (PE) due to thrombosis (blood clot) in a lung
artery is a relatively common cardiovascular emergency [1,2]. The
blood clot commonly travels to the lung arteries from a vein in the leg
[1]. PE and deep vein thrombosis (DVT; when the thrombosis occurs in
the deep veins, most often in the legs) are two clinical presentations of
venous thromboembolism (VTE), with PE being a more severe
manifestation. Empirical estimates of PE incidence rates, based on
European cohort studies, range from 0.15 per 1000 population per year
in Spain [3], 0.189 in Italy [4], 0.342 in the UK [5], 0.50 in Norway [6],
0.51 in Denmark [7], to 0.60 in France [8]. The rates vary partially
depending on the setting of the study and the age of the study popu-
lation. In contrast to population cohort studies, an incidence-based
epidemiological model estimated that the PE incidence rate is 0.95 per
1000 population per year and the occurrence of PE events is almost a
https://doi.org/10.1016/j.thromres.2018.02.009
Received 16 October 2017; Received in revised form 26 January 2018; Accepted 13 February 2018
⁎ Corresponding author.
E-mail address: alexander.cohen@kcl.ac.uk (A. Cohen).
7KURPERVLV5HVHDUFK²
$YDLODEOHRQOLQH)HEUXDU\7KH$XWKRUV3XEOLVKHGE\(OVHYLHU/WG7KLVLVDQRSHQDFFHVVDUWLFOHXQGHUWKH&&%<1&1'OLFHQVHKWWSFUHDWLYHFRPPRQVRUJOLFHQVHV%<1&1'
7
third of a million per year in the European Union (EU) [9].
VTE is associated with increased mortality and morbidity. VTE may
occur in isolation but also as a complication of underlying diseases such
as cancer, medical conditions, and surgical procedures. Most of the
evidence concerning the burden of VTE has been generated in the
United States (US); it has been estimated that 547,596 VTE events occur
annually among US adults (18 years and above) with 277,549 PE, and
78,511 PE with DVT events [10]. Moreover, a recent review estimated
the costs associated with the annual incidence of VTE events at $7–10
billion each year (limited to direct medical cost only) [11]. More spe-
ciﬁcally, a cost modelling study estimated that US VTE annual costs
(including indirect costs) range from $13.5 to 69.3 billion (2011 US
Dollars) with $4.5 to 39.3 billion of these costs being preventable if
improved prophylaxis measures were put in place [12]. Publications on
the burden of VTE in Europe are relatively scarce. A previously pub-
lished modeling study – based on the data from 6 European countries -
estimated that 434,723 PE events and 610,138 post-thrombotic syn-
drome (PTS) events occurs per annum in the EU. The number of VTE-
related deaths was estimated at 543,454 across the EU per annum [9].
The annual VTE costs for the EU, using the same decision tree model as
previously reported in the US [12], range from €1.5 to 13.2 billion
while preventable costs range from €0.5 to 7.3 billion (2014 Euros)
[13]. However, due to the cost assumptions applied in the study, for
instance the use of median costs, the total EU cost is likely to be un-
derestimated.
Immediate treatment of PE is highly eﬀective. Initial treatment is
aimed at life-saving restoration of blood ﬂow through obstructed pul-
monary arteries or at the prevention of potentially fatal recurrences [2].
Traditionally, treatment of PE has consisted of heparin overlapping
with dose-adjusted vitamin K antagonists (VKAs). The introduction of
the non-VKA oral anticoagulants (NOACs) oﬀers more treatment op-
tions.
This study aims to contribute to current scientiﬁc knowledge re-
garding the burden of PE in Europe based on real world data as col-
lected in the PREFER in VTE registry (Prevention of thromboembolic
events- European registry in venous thromboembolism). The focus is on
resource utilization and return to work of patients with PE. Analyses of
mortality and health related quality of life data are reported elsewhere
[14]. Speciﬁc attention is given to the diﬀerences per country, the
diﬀerence between patients with active cancer and those without, and
the association between the burden of the disease and baseline char-
acteristics.
2. Methods
2.1. Setting and study population
The PREFER in VTE registry was a prospective, observational,
multicenter study with a follow-up of 12months. The registry enrolled
3545 consecutive patients from 381 centers (311 active centers i.e.,
centers that enrolled at least one patient) in seven European countries
including Austria, France, Germany, Italy, Spain, Switzerland, and the
UK between January 2013 and July 2014. The study protocol has been
previously described elsewhere [15]. Prior to study commencement,
the registry protocol was approved by the responsible ethics commit-
tees for the participating countries and the relevant hospital-based in-
stitutional review boards. All patients enrolled in the registry ﬁrst
provided written informed consent.
Brieﬂy, patients were eligible to be enrolled into the registry if they
were at least 18 years old, had a symptomatic, objectively conﬁrmed
ﬁrst time or recurrent acute VTE (the index event) deﬁned as either
distal or proximal DVT, PE or both. Eligible patients were recruited
within two weeks of the occurrence of the index event. At baseline
patients were assessed in terms of their demographics, disease, previous
clinical events, risk factors, comorbidities, and presented PE/DVT
symptoms, as well as by their previous treatments. At 1, 3, 6 and
12months follow up, information regarding the occurrence of clinical
events, treatments, resource utilization, health related quality of life,
and treatment satisfaction during each follow up interval was collected
from patients. The current analyses include PE patients only. PE pa-
tients were deﬁned as patients that had either a PE with DVT or a PE
without DVT. A total of 1399 PE patients were recruited in the PREFER
in VTE registry.
2.2. Analyses and statistics
Descriptive statistics of baseline information is provided, including
demographics (age, gender, body mass index [BMI], marital status and
country), clinical factors (with/without previous VTE event, PE with/
without DVT, and (un)provoked1), previous clinical events (within
3 years prior to enrollment: myocardial infarction, coronary heart dis-
ease, percutaneous coronary intervention, atrial ﬁbrillation, transient
ischemic attack, stroke, and bleeding event), risk factors (within past
3months or ongoing: active cancer, prolonged immobiliza-
tion2, > 5 days in bed, varicose veins, and history of major surgery or
trauma), comorbidities (hypertension, congestive heart failure, vascular
disease, dyslipidemia, diabetes, chronic venous insuﬃciency, renal
disease, liver disease, chronic respiratory disease, arthritis, bone frac-
ture/soft tissue trauma, lower extremity paralysis, alcohol use, smoking
history, thrombophilia, and cardiovascular disease), and the presence
of PE symptoms. Due to variable patient accessibility to NOACs and
diﬀerent management patterns, subgroups by country and with/
without active cancer are examined separately. Active cancer is deﬁned
as receiving ongoing treatment for cancer. For regional comparisons,
Austria, Switzerland, and Germany were combined into one pre-speci-
ﬁed region label (DACH). More detail of clinical variables can be found
elsewhere [16].
2.3. Healthcare resource utilization
Treatment medications at baseline, (i.e. the use of heparin, VKA, or
NOACs) and the continuing use of the treatment at each follow up were
presented. Accumulated VTE-related healthcare resource utilization, in
terms of the number of hospitalizations, length of hospital stay (LOS),
the use of intensive care unit (ICU), and ambulatory/oﬃce visits at
12months follow up was estimated. Apart for the total sample, de-
scriptive statistics for country and cancer subgroups were also pre-
sented. The diﬀerence between compared subgroups was evaluated
using chi-square test, Kruskal-Wallis equality-of-populations rank test,
or Wilcoxon rank-sum test (no normal distribution was assumed), when
appropriate.
The dependency between baseline characteristics and LOS was ex-
amined using zero-inﬂated negative binomial regression to address the
issue of the outnumbered zero hospitalization day and over-dispersion
of the distribution. A zero-inﬂated negative binomial regression consists
of two parts: the ﬁrst (inﬂate) part is to predict whether there is an
occurrence of LOS (probability of zero or non-zero), whereas the second
part is to predict the duration of LOS above zero (non-zero value). The
examined baseline characteristics included demographic factors (age,
gender, BMI), previous clinical events, clinical factors (except pro-
voked), co-morbidities (except cardiovascular disease), risk factors, and
presented PE symptoms. A separate model was ﬁtted to explore the
country variation by adding country as an additional co-variate. These
analyses were limited to the total sample.
1 Provoked PE was deﬁned as having prolong immobilization,> 5 days in
bed, or history of major surgery or trauma.
2 Prolonged immobilization was deﬁned as immobilization within the last
3months or ongoing (e.g., travelling for more than 4 h).
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2.4. Return to work
Return to work was expressed as the proportion of patients re-
turning to work during the follow up and when they returned to work.
In the study patients were asked whether they returned to work during
the follow up, and, if applicable, how soon they returned to work and
their productivity level after return in terms of working hours. The
analysis was limited to employed patients and an age limit of 65 years
at baseline, and a variable indicating how soon patients returning to
work was derived. Kaplan-Meier survival analysis was executed to
present the rate and time of employed patients returning to work.
Furthermore, a multivariate Cox proportion hazards regression was
implemented to assess the association between baseline characteristics
(the same as those listed above) and returning to work.
2.5. Missing data
As patients were lost to follow up due to death or incomplete in-
formation, there was missing data at each cross-sectional measurement.
No imputation was conducted for any missing value. However, the
diﬀerence in terms of baseline characteristics between patients who
completed the follow ups and those who did not were tested, using chi
square test, Wilcoxon rank sum test, or t-test, when appropriate.
3. Results
3.1. Patients' characteristics
Table 1 presents patient characteristics at baseline by countries.
Amongst 1399 PE patients at baseline, 25.2% patients were recruited
from France, followed by Italy 23.7%, Spain 23.4%, DACH 17.2% and
UK 10.5%. Mean age was higher in Italy (67.4 years, SD: 17.1) and
lower in DACH (57.8 SD: 16.8), while the percentage of males was
higher in the UK (60.5%) and lower in Italy (47.6%). More than 63% of
patients had PE with DVT in DACH, whereas the proportion was much
lower in the UK (11.6%). Provoked PE was much higher in France
(64.0%) than other countries. Additionally, patients in Italy had the
highest number of risk factors and highest comorbidity: active cancer
rate (12.7%), prolonged immobilization (26.8%:> 5 days in bed
(23.2%)), congestive heart failure (13.9%), vascular disease (16.3%),
and chronic venous insuﬃciency (23.5%). Across all countries, the most
commonly reported PE symptoms include dyspnea and chest pain,
which was greater than 72% and 32%, respectively. The baseline
characteristics of the total sample and cancer subgroup can be found
elsewhere [14].
3.2. Missing data
Compared to the study sample with 12months follow up
(n=1130), those with missing data (n=269) showed a higher pre-
valence of COPD and active cancer and a lower prevalence of varicose
veins. In addition, those with missing data were more likely to smoke.
Data were most often incomplete in the UK.
3.3. VTE related healthcare resource utilization
3.3.1. Medication
As shown in Table 2, the proportion of the total sample treated with
heparin, VKA, and NOAC at baseline was 85.4%, 57.4% and 21.2%,
respectively, and 50.0% of patients were treated with both heparin and
VKA. The use of NOAC was highest in DACH (55.2%) followed by
France (32.6%), and the UK (10.3%). Spain and Italy had the lowest
rates of NOAC use (6.1% and 4.5%, respectively), which was expected
because not all NOACs were reimbursed by these healthcare systems at
the time of the data collection of the PREFER in VTE registry. Active
cancer patients were treated diﬀerently compared to those without
active cancer (VKA: 13.5% vs. 61.5%, p-value< 0.0001; NOACs: 5.9%
vs. 22.7%, p-value< 0.0001).
Table 2 also presents the proportion of patients who continued to
use the baseline treatment at 1-, 3-, 6- and 12-month follow ups.
Whereas the majority of patients with active cancer continued to use
heparin after baseline (> 70% up to 3months), the rate of heparin use
dropped to 9.0% for patients without active cancer. Moreover, > 77%
and 63% of patients without active cancer patients continued to use
baseline VKA or NOACs at 6months, respectively. At 6months, 22%
and 26% of patients who continued to use VKA or NOACs, respectively,
had provoked DVT. Of note, in comparison to other countries, Spain
and Italy had a higher proportion of patients who continued to use
heparin after baseline (23.7% and 15.1% at 3months, respectively). A
similar pattern was observed with patients without active cancer in
both countries.
3.3.2. Hospitalization
Table 3 presents the cumulative frequency (percentage) of VTE-re-
lated healthcare resource utilization by cancer and country subgroups
(the average number of visits and LOS can be found in Appendix
Table 1). By the end of the 12-month follow up, 218 out of 1130 pa-
tients (19.3%) had been re-hospitalized due to VTE-related events (the
reasons for re-hospitalization can be found in Appendix Table 2). If ever
re-hospitalized, the average number of repeat hospitalizations was 1.3
with an average LOS of 8.3 days (calculated as the total number of days
in hospital divided by the number of patients who were hospitalized). A
substantial country variation was observed: the re-hospitalization rate
ranged from 26.2% in the UK to 12.3% in France (p-value<0.0001),
and LOS ranged from 12.9 days in Italy to 3.9 days in France (p-
value= 0.0001). Fig. 1 illustrates the accumulated re-hospitalization
rate and LOS at each follow up by country. France, DACH and Italy had
higher re-hospitalization rates at all time points compared to Spain and
the UK; whereas LOS was relatively diﬀerent between countries with
Italy frequently having the longest LOS. Statistically signiﬁcant diﬀer-
ences were also observed between non-cancer and active cancer pa-
tients – re-hospitalization rate was 18.4% vs. 32.4% (p-value<
0.0001).
The zero-inﬂated negative binomial regression results (Table 4)
suggested that for the ﬁrst (inﬂate) part (estimating the probability of
having no hospital stay) patients with active cancer, bleeding event, or
previous atrial ﬁbrillation had a lower probability of having no hospital
day (more likely to be hospitalized). Whereas having PE with DVT or
living in France, Italy, or Spain decreased the likelihood of being hos-
pitalized. The second part of the analyses (estimating non-zero values)
found that elderly patients and patients with chronic respiratory disease
were more likely to have a higher hospital duration, whereas patients
living in France, with arthritis, or with previous DVT were likely to
have a shorter hospital stay. As there was relatively low variance ex-
plained by the models, the results should be interpreted with caution.
3.3.3. Ambulatory/oﬃce visit
During the 12-month follow up the majority of the patients visited a
physician (88.9%) with an average number of 7.5 visits (Table 3 and
Appendix Table 2). Of patients who had at least one physician visit, the
recruiting physician and the general practitioner (GP) were most often
visited (51.9% and 58.1%, respectively). In comparison, relatively few
visits were made to venous institutions or other healthcare profes-
sionals. In France and DACH, the proportion of patients who had at
least one physician visit visited their GPs in 87.5% and 84.2% of the
cases, respectively, suggesting that GP might play a relatively larger
role in these countries in co-managing PE patients compared to other
countries. Furthermore, active cancer patients did not incur more VTE-
related ambulatory/oﬃce visits than non-cancer patients. Of note, 6.0%
of the total sample did not have any ambulatory/oﬃce visits during 12-
months follow up and the proportion was even higher in some countries
(Italy: 15.1%, the UK: 11.7%).
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Table 1
Patients' characteristics at baseline.
Baseline, % Total
n=1399
France
n= 352
DACH
n=241
Italy
n= 332
Spain
n=327
UK
n=147
Missing
n= 269
Age, years, mean (SD) 62.3 (17.1)⁎ 60.6
(17.2)
57.8 (16.8) 67.4 (17.1) 63.7 (16.8) 59.1 (14.3) 60.8 (18.9)
Under age 65 47.3⁎ 50.3 58.5 33.7 43.7 59.9 46.46
Male 53.2 52.6 56.9 47.6 53.5 60.5 52.8
BMI, mean (SD) 28.2
(6.0)⁎
27.7
(5.5)
28.7
(6.0)
26.9
(5.1)
28.2
(5.2)
31.1
(8.8)
27.6
(7.2)
Highest graduation ⁎
Primary school 32.0 15.6 25.7 50.0 50.5 0 34.2
Secondary school 41.8 44.6 43.6 38.6 30.9 64.0 42.4
Above 21.9 30.1 24.5 9.9 17.1 35.4 19.3
Employment ⁎
Employed 29.66 30.7 38.6 18.5 25.0 48.3 29.28
Marital status ⁎
Single 14.2 15.6 18.7 13.9 13.8 17.0 17.5
Married/living as married
62.2
61.1 60.6 59.6 65.1 66.7 56.9
Separated/divorced 5.3 6.8 6.2 3.6 2.5 10.2 6.3
Widowed 14.4 11.1 10.0 22.0 17.4 6.1 16.4
Other 1.2 0.6 1.2 1.8 0.6 2.7 1.5
Risk factors (within past 3 months or ongoing)
Active cancer 8.6⁎ 7.4 2.9 12.7 12.5 2.7 17.1
Prolong immobilization 17.8⁎ 13.4 17.5 26.8 15.0 15.0 21.2
>5 day in bed 11.8⁎ 7.7 7.1 23.20 10.7 6.1 13.8
Varicose veins 17.5 15.1 16.7 20.5 20.2 11.6 13.0
Major surg. or trauma 14.0 14.5 14.6 16.3 12.2 10.2 13.4
Previous clinical event (within 3 yr. prior to enroll.)
MI 3.7 3.1 4.6 4.5 2.8 4.1 4.5
CAD 3.8⁎ 2.3 7.5 3.6 2.5 4.8 2.6
PCI 2.4 1.4 4.2 2.7 1.5 3.4 2.2
AF 4.7⁎ 1.7 2.9 10.2 4.6 2.7 5.9
TIA 2.7⁎ 0.3 2.5 7.2 0.9 2.0 4.1
Stroke 2.7 2.3 1.3 3.3 4.3 1.4 3.3
Bleeding event 4.2 4.8 1.3 6.3 3.7 4.1 4.5
Clinical factors
Previous VTE event 20.2⁎ 25.3 21.2 15.1 19.3 19.7 19.0
With DVT 46.5⁎ 48.9 63.1 56.6 37.3 11.6 44.6
Provoked 27.5⁎ 64.0 25.8 36.5 24.8 21.8 29.0
Baseline, % Total
n= 1399
France
n= 352
DACH
n=241
Italy
n= 332
Spain
n= 327
UK
n=147
Missing
n= 269
Comorbidities
Hypertension 46.3⁎ 38.6 50.8 55.1 48.6 32.0 42.8
CHF 5.9⁎ 1.7 4.2 13.9 4.6 4.1 6.7
Vascular disease 7.1⁎ 3.1 6.3 16.3 4.9 2.0 9.3
Dyslipidemia 26.4⁎ 24.4 26.0 24.7 34.6 17.7 22.0
Diabetes 11.2 9.7 8.8 15.1 10.1 12.2 10.4
Chronic venous insuﬃciency 14.2⁎ 12.8 6.7 23.5 16.5 3.4 11.2
Renal disease 6.4 5.7 6.3 7.8 6.7 4.8 8.6
Liver disease 2.6 2.0 2.1 4.2 2.1 2.0 3.7
Chronic respiratory disease 10.7⁎ 9.9 4.6 17.8 8.9 10.9 15.6
Arthritis 6.0⁎ 2.6 4.2 5.7 2.8 25.2 5.2
Bone fracture/soft tissue trauma 10.0⁎ 8.2 11.7 13.9 6.4 10.2 11.5
Lower extremity paralysis 1.1⁎ 0.3 0.4 3.0 0.6 0.7 0.7
Alcohol use 15.6⁎ 12.8 16.1 7.6 10.1 51.7 15.7
Smoking history 33.1 29.9 35.3 30.8 33.3 42.2 41.2
Thrombophilia 5.1 4.8 6.2 6.3 4.0 3.4 3.3
Cardiovascular disease 16.8⁎ 10.0 17.9 27.4 14.4 12.9 20.4
PE symptoms present
Dyspnea 75.6⁎ 72.4 73.4 80.1 72.8 83.0 72.5
Chest pain 45.5⁎ 48.3 43.6 31.9 50.8 61.2 42.4
Cough 16. 8⁎ 13.1 20.3 15.7 14.1 28.6 17.1
Hemoptysis 3.4 4.3 1.7 2.4 4.6 4.1 3.0
Syncope 8.2 9.4 7.1 8.1 8.6 6.1 6.7
Palpitations 7.9⁎ 6.0 6.2 11.1 5.8 12.2 10.8
Fever 7.8 7.4 6.2 9.3 9.0 7.5 6.7
Cyanosis 2.2⁎ 2.0 1.7 4.8 0 2.7 2.6
Tachypnea 16.2 12.5 19.9 18.4 15.0 16.3 17.5
Tachycardia 16.7⁎ 11.1 13.7 27.1 15.3 14.3 18.2
Cardiogenic shock 1.5 2.0 1.7 2.4 0.6 0 2.6
Others 7.6⁎ 9.7 9.5 4.5 1.5 19.7 7.4
⁎ Statistically signiﬁcant diﬀerence between compared countries.
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A possibility of selection bias associated with analyzed data should
be considered. As shown in the missing data section above, the study
sample diﬀered from the non-study sample data (due to lost to follow
up). The additional analyses show that the re-hospitalization rate and
average LOS of the current follow up were higher in the group of pa-
tients who did not participate in the next follow up compared to those
who participated in the next follow up.
3.3.4. Return to work
385 patients were employed at baseline and under 65 years old
(27.5% of the total sample), with the average age of 46.7 years old.
Amongst those, 72.2% returned to work by the end of the follow up
(12months). While no statistical diﬀerence in the returning-to-work
rate was observed between countries (79.3% in DACH to 62.1% in the
UK), the active cancer subgroup (n=18) had a much lower rate
(27.8%) compared to the non-cancer group (74.4%, p-value<0.0001).
Fig. 2 presents the Kaplan-Meier estimate of the returning-to-work rate
after the index event in the total study sample. Around day 60 more
than half of the study population (50.3%) had returned to work. Fur-
thermore, amongst patients who returned to work, 35.3% (95/269)
reported reduced working hours at ﬁrst return with an average of 23 h
of work completed per week for 3.1 weeks. For the current work level,
Table 2
Treatment overtime of the total sample and by subgroups.
Total sample Without active cancer With active cancer
% n % n % n
Heparin (LMWH and UFH)
BL 85.4 (1191/1395) 85.4 (1090/1276) 84.9 (101/119)
LMWH 84.0 (985/1173) 83.8 (898/1072) 86.1 (87/101)
Continue. 1m 19.4 (198/1023) 14.3 (134/938) 75.3 (64/85)
LMWH 97.5 (192/197) 97.0 (129/133) 98.4 (63/64)
Continue. 3m 13.5 (131/967) 9.0 (81/897) 71.4 (50/70)
LMWH 99.2 (127/128) 98.7 (77/78) 100 (50/50)
Continue. 6m 9.7 (94/968) 6.6 (60/907) 55.7 (34/61)
LMWH 98.9 (92/93) 100 (59/59) 97.1 (33/34)
Continue. 12m 5.4 (50/918) 3.9 (34/873) 35.6 (16/45)
LMWH 96 (48/50) 94.1 (32/34) 100 (16/16)
VKA
BL 57.4 (801/1395) 61.5 (785/1276) 13.4 (16/119)
Continue. 1m 94.9 (695/732) 94.9 (682/719) 100.0 (13/13)
Continue. 3m 89.7 (618/689) 89.8 (608/677) 83.3 (10/12)
Continue. 6m 77.8 (534/686) 77.9 (526/675) 72.7 (8/11)
Continue. 12m 56.8 (356/627) 56.8 (353/621) 50.0 (3/6)
NOACs
BL 21.2 (296/1394) 22.7 (289/1275) 5.9 (7/119)
Continue. 1m 91.2 (248/272) 90.9 (241/265) 100.0 (7/7)
Continue. 3m 82.3 (214/260) 82.6 (209/253) 71.4 (5/7)
Continue. 6m 63.1 (159/252) 63.0 (155/246) 66.7 (4/6)
Continue. 12m 45.5 (110/242) 45.6 (108/237) 40.0 (2/5)
France DACH Italy Spain UK
% n % n % n % n % n
Heparin (LMWH and UFH)
BL 85.8 (302/352) 80.8 (193/239) 80.1 (265/331) 94.2 (308/327) 84.2 (123/146)
LMWH 77.7 (233/300) 73.5 (136/185) 78.8 (204/259) 95.1 (291/306) 98.4 (121/123)
Continue. 1 m 12.7 (35/276) 8.6 (14/163) 20.6 (47/228) 35.0 (91/260) 11.5 (11/96)
LMWH 97.1 (34/35) 100 (13/13) 95.7 (45/47) 97.8 (89/91) 100 (11/11)
Continue. 3 m 10.7 (29/271) 4.8 (7/146) 15.1 (31/205) 23.7 (61/257) 3.4 (3/88)
LMWH 96.6 (28/29) 100 (7/7) 100 (29/29) 100 (60/60) 100 (3/3)
Continue. 6 m 8.2 (22/268) 2.7 (4/147) 12.0 (25/208) 16.1 (41/254) 2.2 (2/91)
LMWH 95.5 (21/22) 100 (4/4) 100 (24/24) 100 (41/41) 100 (2/2)
Continue. 12m 3.9 (10/257) 2.8 (4/142) 6.2 (12/195) 9.9 (24/242) 0.0 (0/82)
LMWH 80 (8/10) 100 (4/4) 100 (12/12) 100 (24/24) –
VKA
BL 56.6 (198/350) 37.3 (90/241) 66.8 (221/331) 53.2 (174/327) 80.8 (118/146)
Continue. 1 m 95.1 (176/185) 89.0 (73/82) 96.1 (196/204) 94.8 (146/154) 97.2 (104/107)
Continue. 3 m 91.0 (172/189) 79.2 (57/72) 92.6 (176/190) 89.4 (135/151) 89.7 (78/87)
Continue. 6 m 80.9 (148/183) 69.3 (52/75) 85.4 (164/192) 77.3 (116/150) 62.8 (54/86)
Continue. 12m 59.3 (105/177) 53.6 (37/69) 65.2 (103/158) 53.4 (78/146) 42.9 (33/77)
NOACs
BL 32.6 (114/350) 55.2 (132/239) 4.5 (15/332) 6.1 (20/327) 10.3 (15/146)
Continue. 1 m 92.5 (99/107) 88.3 (106/120) 91.7 (11/12) 100.0 (19/19) 92.9 (13/14)
Continue. 3 m 81.0 (85/105) 83.8 (93/111) 76.9 (10/13) 83.3 (15/18) 84.6 (11/13)
Continue. 6 m 57.8 (59/102) 69.8 (74/106) 58.3 (7/12) 55.6 (10/18) 64.3 (9/14)
Continue. 12m 37.6 (38/101) 51.5 (53/103) 44.4 (4/9) 52.9 (9/17) 50.0 (6/12)
LMWH= low molecular weight heparin; UFH=unfractionated heparin; BL= baseline.
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27.8% (76/273) reported reduced working hours with an average of
27 h worked per week for 4.2 weeks. The average working hours per
week at baseline was 37.6. The results are presented per country and
cancer subgroups in Table 5.
Of note the discrepancy between the initial number at risk in the
Kaplan-Meier estimate and the descriptive number stated above is due
to the fact that some patients did not report details regarding days of
work missed. Patients with zero days oﬀ work would automatically be
excluded from the Kaplan-Meier analysis.
The Cox regression results suggested that patients were less likely to
return to work when having active cancer and a smoking history.
Counter-intuitively, the results also suggested that PE patients with
DVT were more likely to return to work (Table 6).
4. Discussion
This study investigated the burden of PE in Europe in terms of VTE-
related healthcare resource utilization and return to work, and it de-
monstrated that a number of factors varied signiﬁcantly. VTE-related
re-hospitalization rate and LOS varied substantially between countries.
PE patients were often co-managed by GPs in DACH and France, and
less so in other countries. The regression results conﬁrmed the country
variation in LOS. The study also showed patients with active cancer
were primarily treated with heparin, while patients without active
cancer received combinations of heparin, VKA, and NOACs. In terms of
return to work, 60% of employed patients returned to work within a
month, but 27.8% had still not returned after one year. Active cancer
was a signiﬁcant predictor for not returning to work.
4.1. Treatment pattern
Due to licensing and reimbursement status of NOACs during the
PREFER in VTE registry, NOACs use varied substantially across the
included countries in our study. This was observed in Spain and Italy
where access to NOACS was limited at the moment of the PREFER study
conduction. Even amongst the countries where NOACs were fully ac-
cessible, NOACs use also varied. For instance, the UK had much lower
NOAC use, compared to DACH and France. This could be due to dif-
ferent national or local treatment guidelines and recommendations. It
was also observed that the use of heparin after baseline varied greatly
among countries. According to treatment guidelines and general prac-
tice, heparin is given to patients within the ﬁrst one to two weeks
during the acute phase of the PE event. However, the data shows that
more than 23% of the patients in Spain and 15% of the patients in Italy
continued to use heparin at 3-month follow up. This pattern was still
observed in both countries even after removing active cancer patients
from the analysis [data not shown]. Local treatment recommendations
and limited access to NOACs explain this observation.
Distinct treatment patterns between PE patients with and without
active cancer were observed. The majority of patients with active
cancer were initially treated with heparin and continued to use heparin
afterwards, whereas patients without active cancer might start with
heparin at a similar rate as that of active cancer patients but stop he-
parin treatment at one month. These observations reﬂect clinical
practice in all countries except for Spain and Italy.
A large proportion of patients who received VKA or NOACs at
baseline continued their treatment after 3months. The standard
Table 3
Accumulated VTE-related healthcare resource utilization by each country (frequency).
Total
N=1130
France
N=316
DACH
N=187
Italy
N=258
Spain
N=266
UK
N=103
n % n % n % n % n % n %
Re-hospitalization 218 19.3% 39 12.3% 45 24.1% 57 22.1% 50 18.8% 27 26.2%
Ambulatory/oﬃce visits
Physician 1005 88.9% 312 98.7% 184 98.4% 192 74.4% 243 91.4% 74 71.8%
Original site 586 51.9% 207 66.3% 92 50.0% 77 40.1% 160 65.8% 50 67.6%
General practitioners 657 58.1% 273 87.5% 155 84.2% 83 43.2% 111 45.7% 35 47.3%
Cardiologists 209 18.5% 127 40.7% 25 13.6% 27 14.1% 24 9.9% 6 8.1%
Internists 170 15.0% 4 1.3% 39 21.2% 52 27.1% 72 29.6% 3 4.1%
Vascular physicians 177 15.7% 77 24.7% 34 18.5% 39 20.3% 22 9.1% 5 6.8%
Pulmonologists 197 17.4% 73 23.4% 24 13.0% 38 19.8% 51 21.0% 11 14.9%
Other physicians 342 30.3% 161 51.6% 50 27.2% 41 21.4% 80 32.9% 10 13.5%
Venous institutions 24 2.1% 1 0.3% – 16 6.2% 1 0.4% 6 5.8%
Other healthcare profs. 107 9.5% 40 12.7% 10 5.3% 34 13.2% 11 4.1% 12 11.7%
None 68 6.0% – 12.3% 1 0.5% 39 15.1% 16 6.0% 12 11.7%
Without active cancer
N=1056
With active cancer
N=74
n % n %
Hospitalization 194 18.4% 24 32.4%
Ambulatory/oﬃce visits
Physician 947 89.7% 58 78.4%
Original site 556 58.7% 30 51.7%
General practitioners 634 66.9% 23 39.7%
Cardiologists 202 21.3% 7 12.1%
Internists 161 17.0% 9 15.5%
Vascular physicians 164 17.3% 13 22.4%
Pulmonologists 183 19.3% 14 24.1%
Other physicians 325 34.3% 17 29.3%
Venous institutions 23 2.2% 1 1.4%
Other healthcare profs. 112 10.6% 5 6.8%
None 59 5.6% 9 12.2%
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treatment duration according to treatment guidelines is 3 months, but
longer periods of treatment are more often recommended for un-
provoked or recurrent PE. Thus, as observed, at 6/12months, there
were 78/57% and 63/45% of patients who continued to use VKA or
NOACs, respectively, receiving extended treatment. However, 20% of
patients who received extended treatment beyond 3months had pro-
voked PE which is inconsistent with the current guidelines. In part this
discrepancy may be related to the concern about recurrent PE, as PE has
a signiﬁcant mortality rate which may lead to increased concern about
stopping anticoagulant therapy. The reason for such practice requires
further investigation.
It should be noted that the observed medication use in the current
study, to a great extent, reﬂects the speciﬁc case mix of patients in-
cluded in the PREFER registry, as well as the variation in the disease
management across countries.
a) Percentage of patients being hospitalized 
N 1 month 3 month 6 month 12 month
France 338 326 318 316
DACH 223 205 200 187
Italy 307 281 271 258
Spain 307 293 281 266
UK 133 115 110 103
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b) Average total hospitalization duration if hospitalized  
N France DACH Italy Spain UK
1 month 14 24 25 12 10
3 month 28 32 38 27 20
6 month 34 38 50 36 23
12 month 36 41 51 50 25
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Fig. 1. Hospitalization by follow-up and country.
a Percentage of patients being hospitalized.
b Average total hospitalization duration if hospitalized.
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4.2. Re-hospitalization
Similarly, there was a large variation in re-hospitalization rate and
LOS between countries. The regression results suggested that in com-
parison to the UK, France, Italy, and Spain were less likely to have re-
hospitalization (Table 4). Patients in France were likely to have a
shorter hospital duration, after controlling for case mix across countries
(Table 1). However, it should be noted that other factors, such as
pressure on cost containment, the healthcare reimbursement system,
and the level of adoption for outpatient VTE treatment in clinical
practices, might all contribute to the observed variations. A similar
country variation in PE mortality rate was observed and a detailed
discussion can be found elsewhere [14].
Furthermore, the regression results suggest that patients living in
France, those having a previous VTE event and those with a history of
arthritis had shorter hospital stays. In France this is likely to be due to
the well-established medical infrastructure which allows the out of
hospital management of anticoagulation. Patients with previous VTE
are likely to be more experienced with anticoagulation and require less
education and hence may be discharged early. The reason for the re-
lationship with arthritis and a shorter length of stay and the other
ﬁnding of PE patients with DVT being more likely to return to work are
both currently unknown and may be due to our testing of many vari-
ables and the play of chance.
The key cost driver of the economic burden associated with PE is
VTE-related LOS [17]. Most recent studies examine the US setting,
whereas only a few studies in the literature report LOS of PE patients in
Europe. A study in Belgium with 54 patients reported average LOS as
14.6 days (SD 12.4) in 1998 [18]; and a modeling study in France in
1999 reported an average LOS of 4.6–6.4 days [19]. A more recent
German study using local insurance data in 2000–2006 reported
average all-cause LOS as 21.4–23.6 days [20]. A Spanish study reported
the trend in hospital admission of PE over a 10-year period, where LOS
was estimated as 12.7 days in 2002 and decreased to 9.99 in 2011 [21].
In addition, an Italian study collecting data from 160 VTE patients re-
ported a LOS of 12.5 days [22]. In comparison to the number observed
in the PREFER in VTE registry, the LOS in Italy and Spain is similar to
that reported in the literature; whereas the diﬀerence between German
ﬁgures might be explained by the fact that PREFER in VTE registry is
restricted to VTE-related re-hospitalizations only. The shorter LOS in
France observed in the PREFER in VTE registry is also reported in the
Table 4
The results of zero-inﬂated negative binomial regression (length of hospital
stay).
Haz. ratio Std. err. P > z [95% conf. interval]
Inﬂate part
Constant 0.638 0.234 0.006 0.180 1.097
Active cancer −1.029 0.347 0.003 −1.710 −0.348
Bleeding event −1.946 0.541 0 −3.006 −0.887
AF −1.033 0.404 0.011 −1.824 −0.242
PE with DVT 0.488 0.194 0.012 0.109 0.868
France 0.769 0.312 0.014 0.158 1.381
Spain 0.577 0.259 0.026 0.070 1.085
Italy 0.643 0.252 0.011 0.149 1.137
Second part
Constant 0.773 0.416 0.063 −0.043 1.589
Age 0.019 0.006 0.002 0.007 0.031
Chronic respiratory
disease
0.905 0.309 0.003 0.299 1.511
Arthritis −0.927 0.368 0.012 −1.648 −0.206
Previous VTE event −0.619 0.248 0.012 −1.105 −0.134
France −1.370 0.303 0 −1.963 −0.777
Likelihood-ratio test of alpha=0: chibar2(01)= 1053.61,
Pr > =chibar2=0.0000.
Vuong test of zero-inﬂated negative binominal vs. standard negative binomial:
z= 3.94, Pr > z=0.0000.
Goodness of ﬁt: Bayesian information criterion (BIC) 2141.575.
Fig. 2. Kaplan-Meier survival estimate of how soon returning to work after index event.
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literature.
4.3. Ambulatory/oﬃce visit
The European Society of Cardiology recommends that patients on
NOACs are followed on a regular basis for on-going review of their
treatment, preferably after 1month initially, and later every 3months.
This study demonstrated that patients were followed-up less regularly
than as recommended by these guidelines.
4.4. Return to work
Our study demonstrated 72.2% of PE patients (limited to those
employed and under age 65 at baseline) return to work within one year
follow-up, with a lower rate for patients with active cancer. This ﬁgure
is consistent with return to work rate following other major illnesses.
The return to work rate within the ﬁrst year after stroke was reported
between 45% to 75%, based on self-reported employment outcomes
[23,24]. A more recent Swedish publication, using insurance sickness
leave data, reported return to work rate following stroke was 74.7%, at
the end of 6-year follow up [25]. Following myocardial infarction (MI),
a US study utilizing the data gathered from the VIRGO study reported
84% of patients return to work by 12months [26].
Publications on long term outcomes of PE/DVT in terms of return to
work, or even disability/employment are relatively scarce. A study in
Norway investigated work-related disability in patients with VTE
compared with those without VTE in a population-based cohort [27].
The study estimated that patients with VTE had between a 17–37%
increased risk of work-related disability than those without VTE. The
study also indicated that the risk of work-related disability is
signiﬁcantly associated with DVT rather than PE (without DVT) [27].
Our study was not consistent with this ﬁnding and showed that PE
patients with DVT were more likely to return to work. However, due to
the diﬀerences in the length of follow up, demographics, clinical
characteristics of the study population and research focus, the com-
parison between these two studies is not straight forward. Our study
focused on return to work within 1 year follow-up only, whereas the
median duration of follow up was 12.3 years in the Norway study [28].
Of note, the work-loss seen in this study may in part reﬂect the
presence of co-morbidities. This work-loss adds to the indirect costs
associated with PE and emphasizes the need for eﬀective primary and
secondary preventions and improving the care of PE patients.
4.5. Strengths and limitations
The PREFER in VTE registry provides a rich data source of clinical
epidemiology, management and outcomes of VTE patients in a real-
world setting. It is one of largest prospective disease registries in VTE
and its focus on seven European countries provides a much needed
addition to the relatively scarce data on PE from this continent. To the
authors' best knowledge, there are no other studies that have explored
country variation in VTE-related HCRU and work loss.
A typical limitation of most observational studies is that data may
be missing. No corrections such as multiple imputation was made and
this needs to be considered in the interpretation of the results. As it is
likely that the patients with comorbidities are more often missing, the
burden of PE may be underestimated.
5. Conclusion
Pulmonary embolism related healthcare resource utilization and
(not) return to work were substantial. 27.8% of employed patients did
not return to work after one year. These outcomes diﬀered between
countries and between patients with active cancer and those without
active cancer. A large amount of country speciﬁc information on patient
characteristics, re-hospitalization, length of hospital stay, and return to
work concerning the excess burden of illness for PE patients was pro-
vided to enhance current knowledge on the economic burden for so-
ciety in Europe.
Table 5
Return to work and working hour/duration, by cancer and country subgroups.
Total
n=385
Without active
cancer
n=367
With active
cancer
n= 18
France
n=102
DACH
n=87
Italy
n=54
Spain
n= 76
UK
n=66
Return to work
Yes, % (n) 72.2% (278/385) 74.4% (273/367) 27.8% (5/18) 71.6% (73/102) 79.3% (69/87) 74.1% (40/54) 72.4% (55/76) 62.1% (41/66)
First return reduced work
Yes, % (n) 35.3% (95/269) 35.2% (93/264) 40.0% (2/5) 29.2% (21/72) 34.8% (23/66) 55.6% (20/36) 23.6% (13/55) 45.0% (18/40)
First return reduced work, duration
n 91 89 2 21 22 17 13 18
Week, mean (SD) 3.12 (3.3) 3.1 (3.3) 2.5 (2.1) 4.8 (4.6) 3.2 (3.8) 3.3 (2.3) 1.6 (0.8) 1.9 (1.3)
First return reduced work, hours
n 95 93 2 21 23 20 13 18
Hour per week, mean
(SD)
22.9 (13.6) 22.9 (13.7) 22.5 (10.6) 29.5 (14.2) 20.7 (11.9) 28.1 (13.2) 10.8 (12.3) 21.1 (9.6)
Current work same as before
No, % (n) 27.8% (76/273) 27.6% (74/268) 40.0% (2/5) 30.6% (22/72) 22.1% (15/68) 44.7% (17/38) 12.7% (7/55) 37.5% (15/40)
Current work reduced, duration
n 71 69 2 21 14 14 7 15
week, mean (SD) 4.2 (5.3) 4.2 (5.3) 4.5 (4.9) 4.4 (4.6) 4.6 (4.9) 6.4 (9.0) 2.9 (0.7) 2.1 (1.1)
Current work reduced, hours
n 76 74 2 22 15 17 7 15
Hour per week, mean
(SD)
26.7 (14.5) 26.8 (14.7) 22.5 (10.6) 30.3 (15.8) 25.8 (13.0) 28.2 (14.2) 11.3 (10.5) 27.8 (12.8)
Table 6
Cox regression result.
Coef. Std. err. P > z [95% conf. interval]
PE with DVT 1.422 0.187 0.007 1.099 1.841
Active cancer 0.717 0.099 0.017 0.547 0.941
Smoking history 0.186 0.108 0.004 0.059 0.580
Goodness of ﬁt: Bayesian information criterion (BIC) 2525.296
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Appendix A
Table 1
Accumulated VTE-related healthcare resource utilization by each country/cancer subgroups (magnitude)
Total
N= 1130
France
N=316
DACH
N=187
Italy
N=258
n Mean SD n Mean SD n Mean SD n Mean SD
Hospitalization
Number of hospitalization 214 1.3 0.7 38 1.1 0.3 43 1.3 0.9 57 1.5 0.9
Length of hospital stay, total 203 8.3 10.8 36 3.9 8.3 41 5.9 6.6 51 12.9 12.8
Length of hospital stay, per stay 203 6.2 7.3 36 3.2 5.0 41 5.4 6.3 51 8.3 6.3
Days in ICU, total 170 0.3 1.4 30 0.1 0.3 39 0.3 0.8 36 0.1 0.3
Ambulatory/oﬃce visits
Any physician 932 7.6 7.8 293 8.1 5.3 168 11.5 9.2 169 8.3 11.6
Original site 551 2.8 3.8 199 2.4 1.1 84 3.1 3.1 71 5.8 9.0
General practitioners 619 5.2 6.3 258 4.1 3.8 145 8.7 7.5 75 7.4 10.2
Cardiologists 198 1.9 1.8 122 1.8 1.2 23 1.7 1.1 24 2.3 2.9
Internists 164 3.5 4.3 4 9.5 17.0 37 4.4 5.0 48 3.9 3.8
Vascular physicians 169 1.8 1.1 74 1.9 1.2 32 1.7 1.1 36 1.8 1.1
Pulmonologists 188 1.8 1.1 70 1.8 1.2 22 1.9 1.6 36 1.9 0.9
Other physicians 330 2.3 2.2 156 2.2 1.8 49 2.1 1.8 37 2.7 3.3
Venous institutions 23 3.3 3.8 1 1.0 – – – – 16 2.4 2.3
Any other healthcare professionals 104 8.6 37.4 39 6.6 8.8 9 14.3 14.2 26 1.0 1.8
Spain UK Without active cancer With active cancer
N=226 N=103 N=1056 N=74
n Mean SD n Mean SD n Mean SD n Mean SD
Hospitalization
Number of hospitalization 50 1.2 0.7 26 1.3 0.5 190 1.3 0.7 24 1.3 0.6
Length of hospital stay, total 50 10.2 12.8 25 5.4 6.0 180 7.5 10.0 23 14.5 14.7
Length of hospital stay, per stay 50 8.1 10.2 25 4.1 4.1 180 5.5 5.6 23 11.9 14.1
Days in ICU, total 44 0.7 2.0 21 0.5 2.2 154 0.3 1.3 16 0.9 2.1
Ambulatory/oﬃce visits
Any physician 237 4.7 4.5 65 3.5 3.5 878 7.7 7.9 54 4.8 4.2
Original site 155 2.2 1.2 42 2.0 1.1 522 2.9 3.8 29 2.4 1.4
General practitioners 109 2.3 2.7 32 2.5 2.8 597 5.2 6.3 22 3.4 5.1
Cardiologists 23 1.6 1.0 6 3.7 6.1 191 1.8 1.8 7 2.7 1.9
Internists 72 2.6 2.1 3 1.0 0.0 156 3.5 4.4 8 3.3 2.2
Vascular physicians 22 1.7 0.9 5 0.8 0.4 157 1.8 1.1 12 1.8 0.9
Pulmonologists 50 1.7 1.0 10 1.3 0.5 174 1.8 1.1 14 1.4 0.6
Other physicians 78 2.3 2.6 10 2.2 1.3 313 2.3 2.3 17 1.6 1.0
Venous institutions 1 1.0 – 5 7.2 5.8 22 3.4 3.8 1 1.0 .
Any other healthcare professionals 11 39.3 112.5 19 2.4 2.2 100 8.8 38.1 4 2.3 3.3
Table 2
Reason for re-hospitalization
% N
VTE 18.6 (41/221)
Bleeding event 9.3 (20/215)
Other reasons 75.0 (177/236)
Major surgery or trauma 11.4 (24/211)
Stroke 2.8 (6/214)
Arterial embolism 2.4 (5/211)
TIA 1.9 (4/212)
Myocardial infraction 1.4 (3/212)
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